Semaglutide and topiramate come up together because both can affect appetite and weight, but they are very different drugs. Topiramate is also the "topiramate" half of Qsymia, which adds to the confusion.
Quick answer: Semaglutide is a GLP-1 receptor agonist that reduces appetite and is used for diabetes and weight management. Topiramate is an anti-seizure and migraine drug that can reduce appetite as a side effect and is combined with phentermine in the weight-loss drug Qsymia. Qsymia is not a GLP-1. In the research referenced, semaglutide generally produced greater average weight loss than phentermine-topiramate. The two can sometimes be used together under medical supervision, but they work through entirely different mechanisms.
Is Qsymia a GLP-1?
No. Qsymia is not a GLP-1 medication. It combines two older drugs: phentermine, a stimulant that suppresses appetite, and topiramate, an anti-seizure medication that also reduces appetite and increases fullness. GLP-1 drugs like semaglutide work in a completely different way, acting on GLP-1 receptors to slow digestion and reduce hunger signals in the brain. So while both Qsymia and semaglutide are used for weight loss, they belong to separate drug classes with distinct mechanisms, and topiramate by itself is not a GLP-1 either.
Semaglutide vs topiramate (and Qsymia) for weight loss
| Feature | Semaglutide | Topiramate / Qsymia |
|---|---|---|
| Drug class | GLP-1 receptor agonist | Anti-seizure (topiramate) + stimulant (phentermine in Qsymia) |
| How it works | Slows digestion, reduces appetite | Reduces appetite, increases fullness |
| Form | Weekly injection (or oral) | Oral capsule |
| Average weight loss | Generally greater in referenced studies | Effective but generally less than semaglutide |
| Is it a GLP-1? | Yes | No |
In the research referenced, semaglutide produced a larger average percent weight reduction than phentermine-topiramate, though both are recognized weight-management options.
Can you take topiramate and semaglutide together?
There is no specific rule that prohibits combining topiramate and semaglutide, and some clinicians do use multiple weight-management approaches together in select cases. However, combining medications that both affect appetite should only be done under medical supervision, because side effects can add up and the combination needs monitoring. Topiramate has its own side-effect profile, including effects on cognition and tingling sensations for some people, and semaglutide commonly causes GI effects. A clinician weighs the benefits and risks for your specific situation before combining them.
Not sure which GLP-1 is right for you?
Take a 2-minute assessment and get a personalized recommendation after licensed provider review.
Take the Assessment →Qsymia vs Ozempic, Wegovy, and Zepbound
People often compare Qsymia with the popular injectables. Ozempic and Wegovy contain semaglutide (a GLP-1), and Zepbound contains tirzepatide (a GLP-1 and GIP drug), while Qsymia is the phentermine-topiramate combination. The injectables generally produced larger average weight loss in the drug classes studied, but Qsymia is an oral once-daily option, which some people prefer. Cost, insurance coverage, side effects, and whether you want an injection or a pill all factor into the choice. There is no single best option for everyone.
Is topiramate a GLP-1?
No. Topiramate on its own is an anti-seizure and migraine medication, not a GLP-1. Its appetite-reducing effect is part of why it is used in Qsymia for weight management, but the mechanism is unrelated to GLP-1 receptor activity. If you see topiramate described as a weight-loss drug, that refers to this appetite effect and its role in Qsymia, not to it being a GLP-1.
Which is right for you?
The choice depends on your health, preferences, side-effect tolerance, and what your clinician recommends. Semaglutide tends to produce greater average weight loss and is a weekly injection (with an oral form also available), while Qsymia is a daily oral capsule. For people seeking medically supervised weight management with a GLP-1, FormBlends connects patients with licensed US pharmacies for compounded semaglutide and tirzepatide. See our semaglutide options or compare providers with our provider comparison tool.
Frequently asked questions
Is Qsymia a GLP-1?
No. Qsymia combines phentermine and topiramate, not a GLP-1.
Is topiramate a GLP-1?
No. Topiramate is an anti-seizure and migraine drug that can reduce appetite.
Can you take topiramate and semaglutide together?
There is no specific prohibition, but combine them only under medical supervision.
Which causes more weight loss, semaglutide or Qsymia?
Semaglutide generally produced greater average weight loss in the referenced research.
Qsymia vs Ozempic, which is better?
They are different classes; injectables generally produced larger weight loss, but Qsymia is an oral option. The best choice is individual.
Is Qsymia an injection?
No. Qsymia is a once-daily oral capsule.
Is semaglutide better than topiramate?
For weight loss, semaglutide generally produced more weight loss, but the right choice depends on your situation and clinician.
Sources
- GoodRx, Qsymia vs Wegovy comparison: https://www.goodrx.com/conditions/weight-loss/qsymia-vs-wegovy
- ICER summary of obesity medications: https://pmc.ncbi.nlm.nih.gov/articles/PMC10387935/
Related guides
- Tirzepatide vs Qsymia: GLP-1 vs Phentermine/Topiramate
- Semaglutide vs Metformin for Weight Loss: $4 Drug vs $1000 Drug
- Qsymia vs Zepbound: An Older Combination Pill Against the Newest GLP-1
- Glp-1 vs Qsymia Comparison Guide
- GLP-1 vs Phentermine: Two Different Drug Classes, Two Different Use Cases
- Weight Loss With vs Without GLP-1: Do You Need the Drug?
See your options in about 2 minutes
Take the free quiz and see what fits you. Quick, private, and no commitment to continue.
See my options →